Mozart Therapeutics

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Mozart Therapeutics Raises $25 Million in Expanded Series A Financing to Support Clinical Development of First-in-Class CD8 Treg Modulators for the Trea...

Details:

The proceeds will be used to advance first-in-class CD8 Treg Modulators including MTX-101, a bispecifc autoimmune checkpoint inhibitor, into first-in-human clinical trials for the treatment of autoimmune diseases and to support pipeline expansion.

Lead Product(s): MTX-101

Therapeutic Area: Gastroenterology Product Name: MTX-101

Highest Development Status: PreclinicalProduct Type: Large molecule

Partner/Sponsor/Collaborator: Pfizer Ventures

Deal Size: $80.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing June 07, 2023

ASK
US

Upload
your Marketing & Sales content

Mozart Therapeutics

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Mozart Therapeutics Launches with $55 Million Series A Financing to Develop Disease Modifying Therapeutics for Autoimmune and Inflammatory Diseases

Details:

The company will use the Series A funds to progress its lead CD8 Treg Modulator into the clinic while also advancing additional programs generated from its novel platform.

Lead Product(s): Undisclosed

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: DiscoveryProduct Type: Undisclosed

Partner/Sponsor/Collaborator: ARCH Venture Partners

Deal Size: $55.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing October 26, 2021

ASK
US

Upload
your Marketing & Sales content